Search results
Showing 1486 to 1500 of 1536 results for do not do recommendations
Read NICE's statement on modern slavery and human trafficking.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
NICE's past research and projects
A step-by-step summary about how we develop our technology appraisal guidance.
Our science policy and research programme team produces high-quality, impactful research.
NICE guidelines are evidence-based recommendations for health and care in England and Wales.
Help us improve NICE: take part in research to help us develop better products and services.
We want you to help NICE to develop our guidance for NHS and care services.
Join NICE's people and communities network
Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.
Read NICE's patient and public involvement policy.
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
Involving you in the development of NICE guidance.
Find individual child abuse and neglect recommendations quickly and links to full guideline.